Ridgetech（RDGT）株式概要リジテック社は中華人民共和国において医薬品およびその他のヘルスケア製品の卸売業を営んでいる。 詳細RDGT ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6報酬当社が推定した公正価値より100%で取引されている 過去5年間の収益は年間6.6%増加しました。 リスク分析過去1年間で株主の希薄化は大幅に進んだ US市場と比較して、過去 3 か月間の株価の変動が非常に大きい意味のある時価総額がありません ( $197K )すべてのリスクチェックを見るRDGT Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$1.4799.4% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-21m159m2016201920222025202620282031Revenue US$109.3mEarnings US$3.2mAdvancedSet Fair ValueView all narrativesRidgetech, Inc. 競合他社MangoceuticalsSymbol: NasdaqCM:MGRXMarket cap: US$6.0mPolomar Health ServicesSymbol: OTCPK:PMHSMarket cap: US$13.5mHealthWarehouse.comSymbol: OTCPK:HEWAMarket cap: US$7.4mBlum HoldingsSymbol: OTCPK:BLMHMarket cap: US$8.2m価格と性能株価の高値、安値、推移の概要Ridgetech過去の株価現在の株価US$1.4752週高値US$760.5052週安値US$1.23ベータ-0.341ヶ月の変化-63.70%3ヶ月変化-99.42%1年変化-99.05%3年間の変化-99.90%5年間の変化-99.90%IPOからの変化-99.90%最新ニュースNew Risk • Mar 25New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$2.43m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (35% average weekly change). Shareholders have been substantially diluted in the past year (196% increase in shares outstanding). Market cap is less than US$10m (US$2.43m market cap).Reported Earnings • Mar 08First half 2026 earnings released: US$0.01 loss per share (vs US$0.42 loss in 1H 2025)First half 2026 results: US$0.01 loss per share (improved from US$0.42 loss in 1H 2025). Revenue: US$62.8m (down 12% from 1H 2025). Net loss: US$60.2k (loss narrowed 97% from 1H 2025).New Risk • Feb 13New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 6.9% per year over the past 5 years. Shareholders have been substantially diluted in the past year (196% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported March 2025 fiscal period end). Market cap is less than US$100m (US$30.9m market cap).Buy Or Sell Opportunity • Jan 15Now 27% undervaluedOver the last 90 days, the stock has risen 47% to US$2.36. The fair value is estimated to be US$3.22, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.8% over the last 3 years. Earnings per share has grown by 61%.お知らせ • Dec 30Ridgetech, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.Ridgetech, Inc. has filed a Follow-on Equity Offering in the amount of $200 million. Security Name: Ordinary Shares Security Type: Common Stock Transaction Features: At the Market OfferingBuy Or Sell Opportunity • Nov 20Now 27% undervaluedOver the last 90 days, the stock has risen 236% to US$4.17. The fair value is estimated to be US$5.72, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.8% over the last 3 years. Earnings per share has grown by 61%.最新情報をもっと見るRecent updatesNew Risk • Mar 25New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$2.43m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (35% average weekly change). Shareholders have been substantially diluted in the past year (196% increase in shares outstanding). Market cap is less than US$10m (US$2.43m market cap).Reported Earnings • Mar 08First half 2026 earnings released: US$0.01 loss per share (vs US$0.42 loss in 1H 2025)First half 2026 results: US$0.01 loss per share (improved from US$0.42 loss in 1H 2025). Revenue: US$62.8m (down 12% from 1H 2025). Net loss: US$60.2k (loss narrowed 97% from 1H 2025).New Risk • Feb 13New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 6.9% per year over the past 5 years. Shareholders have been substantially diluted in the past year (196% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported March 2025 fiscal period end). Market cap is less than US$100m (US$30.9m market cap).Buy Or Sell Opportunity • Jan 15Now 27% undervaluedOver the last 90 days, the stock has risen 47% to US$2.36. The fair value is estimated to be US$3.22, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.8% over the last 3 years. Earnings per share has grown by 61%.お知らせ • Dec 30Ridgetech, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.Ridgetech, Inc. has filed a Follow-on Equity Offering in the amount of $200 million. Security Name: Ordinary Shares Security Type: Common Stock Transaction Features: At the Market OfferingBuy Or Sell Opportunity • Nov 20Now 27% undervaluedOver the last 90 days, the stock has risen 236% to US$4.17. The fair value is estimated to be US$5.72, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.8% over the last 3 years. Earnings per share has grown by 61%.お知らせ • Nov 13Ridgetech, Inc., Annual General Meeting, Dec 12, 2025Ridgetech, Inc., Annual General Meeting, Dec 12, 2025, at 09:00 China Standard Time. Location: 5th floor, building 6, no. 100, 18th street, baiyang sub-district, qiantang district, zhejiang province, p. r. china, 310008., hangzhou Chinaお知らせ • Oct 23Ridgetech, Inc. has withdrawn its Follow-on Equity Offering in the amount of $5 million.Ridgetech, Inc. has withdrawn its Follow-on Equity Offering in the amount of $5 million. Security Name: Ordinary Shares Security Type: Common Stockお知らせ • Sep 26Ridgetech, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.Ridgetech, Inc. has filed a Follow-on Equity Offering in the amount of $5 million. Security Name: Ordinary Shares Security Type: Common StockReported Earnings • Jul 29Full year 2025 earnings released: US$0.26 loss per share (vs US$2.93 loss in FY 2024)Full year 2025 results: US$0.26 loss per share (improved from US$2.93 loss in FY 2024). Revenue: US$120.0m (down 22% from FY 2024). Net loss: US$1.46m (loss narrowed 66% from FY 2024).New Risk • Mar 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$15m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 23% per year over the past 5 years. Shareholders have been substantially diluted in the past year (267% increase in shares outstanding). Market cap is less than US$10m (US$5.80m market cap).お知らせ • Feb 07China Jo-Jo Drugstores, Inc., Annual General Meeting, Feb 25, 2025China Jo-Jo Drugstores, Inc., Annual General Meeting, Feb 25, 2025, at 10:00 China Standard Time. Location: located at 4th floor, building 5, renxin yaju, gon, gong shu district, zhejiang, hangzhou city, ChinaNew Risk • Jan 30New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.82m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$15m free cash flow). Earnings have declined by 23% per year over the past 5 years. Shareholders have been substantially diluted in the past year (267% increase in shares outstanding). Market cap is less than US$10m (US$9.82m market cap).Reported Earnings • Jan 16First half 2025 earnings released: US$0.42 loss per share (vs US$0.77 loss in 1H 2024)First half 2025 results: US$0.42 loss per share. Revenue: US$71.2m (down 9.4% from 1H 2024). Net loss: US$2.28m (loss widened 146% from 1H 2024).分析記事 • Oct 30China Jo-Jo Drugstores, Inc. (NASDAQ:CJJD) Stocks Shoot Up 32% But Its P/S Still Looks ReasonableChina Jo-Jo Drugstores, Inc. ( NASDAQ:CJJD ) shareholders are no doubt pleased to see that the share price has bounced...New Risk • Oct 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 36% per year over the past 5 years. Shareholders have been substantially diluted in the past year (295% increase in shares outstanding). Minor Risk Market cap is less than US$100m (US$14.8m market cap).New Risk • Aug 09New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.72m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 36% per year over the past 5 years. Shareholders have been substantially diluted in the past year (294% increase in shares outstanding). Market cap is less than US$10m (US$9.72m market cap). Minor Risk Share price has been volatile over the past 3 months (12% average weekly change).Reported Earnings • Aug 01Full year 2024 earnings released: US$2.93 loss per share (vs US$41.46 loss in FY 2023)Full year 2024 results: US$2.93 loss per share (improved from US$41.46 loss in FY 2023). Revenue: US$154.5m (up 3.8% from FY 2023). Net loss: US$4.23m (loss narrowed 80% from FY 2023).お知らせ • Jun 01China Jo-Jo Drugstores, Inc. Announces Resignation of Pingfan Wu as Member of the Board of DirectorsChina Jo-Jo Drugstores, Inc. announced that Ms. Pingfan Wu has resigned from her position as a member of the board of directors (the "Board") due to personal reasons, effective on May 31, 2024. The resignation of Ms. Wu did not result from any disagreement with the Company on any matter relating to the Company's business operations, financial reporting or controls, policies or practices.お知らせ • Apr 30China Jo-Jo Drugstores, Inc. has filed a Follow-on Equity Offering in the amount of $1.53 million.China Jo-Jo Drugstores, Inc. has filed a Follow-on Equity Offering in the amount of $1.53 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 900,000 Price\Range: $1.7 Transaction Features: Registered Direct OfferingNew Risk • Apr 01New major risk - Revenue and earnings growthRevenue has declined by 9.5% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 9.5% over the past year. Shareholders have been substantially diluted in the past year (65% increase in shares outstanding). Market cap is less than US$10m (US$5.30m market cap). Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Share price has been volatile over the past 3 months (13% average weekly change).New Risk • Jan 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (294% increase in shares outstanding). Market cap is less than US$10m (US$7.47m market cap). Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Share price has been volatile over the past 3 months (12% average weekly change). Share price has been volatile over the past 3 months (12% average weekly change).お知らせ • Nov 15China Jo-Jo Drugstores, Inc., Annual General Meeting, Nov 16, 2023China Jo-Jo Drugstores, Inc., Annual General Meeting, Nov 16, 2023, at 21:00 US Eastern Standard Time. Location: Hai Wai Hai Tongxin Mansion Floor 6, Gong Shu District, Hangzhou City, Zhejiang Province, P. R. China, 310008 Zhejiang China Agenda: To elect six directors to serve until the next Annual Meeting or until their successors are duly elected and qualified;to ratify the appointment of YCM CPA, Inc. as the Company's independent registered public accounting firm for the fiscal year ending March 31,2024; to approve by ordinary resolution the proposed reverse stock split and consolidation of the Company's issued and outstanding ordinary shares;to approve by ordinary resolution the increase of authorized share capital;to approve by special resolution the Amendment of the Memorandum and Articles of Association of the Company to effect the reverse stock split and consolidation of the Company's issued and outstanding ordinary shares, and the increase of authorized share capital;to approve the Third Amended and Restated 2010 Equity Incentive Plan; and to transact such other business as may properly come before the Annual Meeting or any adjournment thereof.New Risk • Jun 27New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.89m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (36% average weekly change). Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Market cap is less than US$10m (US$9.89m market cap).お知らせ • Jun 18China Jo-Jo Drugstores Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price DeficiencyOn June 16, 2023, China Jo-Jo Drugstores, Inc. announced that on June 15, 2023, the company has received a notification letter from Nasdaq Listing Qualifications Department (‘Nasdaq’) notifying the Company that it is not in compliance with the minimum bid price requirement from May 3, 2023 through June 14, 2023. As set forth in Nasdaq Listing Rules 5550(a)(2) (‘Nasdaq Listing Rule’), it requires that the closing bid price for the Company's ordinary shares listed on Nasdaq be maintained at a minimum of USD 1.00 and failure to meet it for 30 consecutive trading days constitutes a compliance deficiency. The notification has no immediate effect on the listing of the Company's ordinary shares on Nasdaq. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days from the date of notification, or until December 12, 2023, to regain compliance with the minimum bid price requirement, during which time the Company's ordinary shares will continue to trade on the Nasdaq Capital Market. If at any time during this 180 day period, or before December 12, 2023, the closing bid price of the Company's ordinary shares is at least USD 1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written notification that the Company has achieved compliance with the minimum bid price requirement. In the event the Company does not regain compliance by December 12, 2023, the Company may be eligible for additional time to regain compliance, if the Company provide written notice of its intention to cure the deficiency during the second compliance period and is in compliance with the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market. The company intends to monitor the closing bid price of its ordinary shares between now and December 12, 2023. In the event the Company is not eligible for additional time to regain compliance with the Nasdaq requirements towards the end of the first compliance period, the company's Board of Directors will consider options that may be available to achieve compliance.Reported Earnings • Jun 16Full year 2023 earnings released: US$2.07 loss per share (vs US$0.92 loss in FY 2022)Full year 2023 results: US$2.07 loss per share (further deteriorated from US$0.92 loss in FY 2022). Revenue: US$148.8m (down 9.5% from FY 2022). Net loss: US$21.1m (loss widened US$17.9m from FY 2022).Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Independent Director Pingfan Wu was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Jul 29Full year 2022 earnings released: US$0.92 loss per share (vs US$2.39 loss in FY 2021)Full year 2022 results: US$0.92 loss per share (up from US$2.39 loss in FY 2021). Revenue: US$164.4m (up 24% from FY 2021). Net loss: US$3.19m (loss narrowed 61% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has fallen by 43% per year, which means it is performing significantly worse than earnings.Seeking Alpha • Jul 28China Jo - Jo Drugstores GAAP EPS of -$0.92, revenue of $164.39MChina Jo - Jo Drugstores press release (NASDAQ:CJJD): FY GAAP EPS of -$0.92. Revenue of $164.39M (+23.5% Y/Y). Revenue increased by 23.5% to $164.39 million for the fiscal year ended March 31, 2022 from $133.13 million for the same period of last year. Gross profit increased by 24.9% to $36.52 million for the fiscal year ended March 31, 2022 from $29.24 million for the same period of last year. Gross margin increased by 0.2 percentage points to 22.2% for the fiscal year ended March 31, 2022 from 22.0% for the same period of last year. Revenue for the fiscal year ended March 31, 2022 increased by $31.25 million, or 23.5%, to $164.39 million from $133.13 million for the same period of last year. The increase in revenue was primarily due to the growth in retail drugstores, online pharmacy and wholesale business.お知らせ • Apr 28China Jo-Jo Drugstores Regains Compliance with Nasdaq Minimum Bid Price RequirementChina Jo-Jo Drugstores, Inc. announced on April 27, 2022 that it received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on April 25, 2022, notifying the Company that it has regained compliance with the Nasdaq Capital Market's minimum bid price requirement and the matter is closed. On July 26, 2021, the Company was first notified by Nasdaq its failure to maintain a minimum bid price of $1.00 per share for 30 consecutive trading days under Nasdaq Listing Rules 5550(a)(2) and 5810(c)(3)(A), and was given its first 180-day extension, or until January 24, 2022 to regain compliance. On January 25, 2022, the Company received a second 180-day extension from Nasdaq or until July 25, 2022 to regain compliance. Effective April 7, 2022, the Company effected a 1-for-12 reverse stock split. The letter dated April 25, 2022 the Company received from Nasdaq noted that as of April 22, 2022, the Company evidenced a closing bid price of its ordinary shares at or greater than the $1.00 per share minimum requirement for the last 11 consecutive business days, from April 7, 2022 through April 22, 2022. Nasdaq stated that accordingly, Jo-Jo Drugstores has regained compliance with Nasdaq Marketplace Rule 5550(a)(2) and the matter is closed.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Independent Director Pingfan Wu was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jan 27China Jo-Jo Drugstores Granted Extension to Meet Nasdaq Minimum Bid Price RequirementChina Jo-Jo Drugstores, Inc. announced that on January 25, 2022, the Company received another 180 calendar day extension from Nasdaq's Listing Qualifications Department to meet Nasdaq's continuing listing requirements by maintaining a minimum bid price per share of $1.00 for a minimum of 10 consecutive trading days. The Company now has until July 25, 2022 to regain compliance. If at any time before July 25, 2022, the bid price of the Company's ordinary shares closes at or above $1.00 per share for a minimum of 10 consecutive trading days, the Company will regain compliance with the Nasdaq Listing Rules, and the matter will be closed. The Company was first notified by Nasdaq of its failure to maintain a minimum bid price of $1.00 per share for 30 consecutive trading days under Nasdaq Listing Rules 5550(a)(2) and 5810(c)(3)(A) on July 26, 2021, and was given until January 24, 2022 to regain compliance.Reported Earnings • Jan 22First half 2022 earnings releasedFirst half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (up US$1.73m from 1H 2021). Profit margin: (up from net loss in 1H 2021). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.Board Change • Nov 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Independent Director Pingfan Wu was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Jul 01Full year 2021 earnings released: US$0.20 loss per share (vs US$0.18 loss in FY 2020)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2021 results: Revenue: US$133.1m (up 14% from FY 2020). Net loss: US$8.12m (loss widened 40% from FY 2020). Like-for-like sales growth: Down 1.3% vs FY 2020 Over the last 3 years on average, earnings per share has increased by 62% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Mar 05New 90-day low: US$0.98The company is down 11% from its price of US$1.10 on 04 December 2020. The American market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is down 10.0% over the same period.Reported Earnings • Feb 14Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.016 profit in 3Q 2020)The company reported a soft third quarter result with weaker earnings and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: US$35.5m (up 6.5% from 3Q 2020). Net loss: US$6.26m (down US$6.79m from profit in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.分析記事 • Feb 09China Jo-Jo Drugstores' (NASDAQ:CJJD) Stock Price Has Reduced 24% In The Past Five YearsIdeally, your overall portfolio should beat the market average. But the main game is to find enough winners to more...Is New 90 Day High Low • Feb 06New 90-day high: US$1.24The company is up 16% from its price of US$1.07 on 06 November 2020. The American market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is up 2.0% over the same period.Is New 90 Day High Low • Jan 12New 90-day high: US$1.15The company is up 22% from its price of US$0.94 on 13 October 2020. The American market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is up 2.0% over the same period.お知らせ • Dec 24China Jo-Jo Drugstores Regains Compliance with Nasdaq Minimum Bid Price RequirementChina Jo-Jo Drugstores, Inc., on December 23, 2020 announced that it has received notification from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which concerns minimum bid price listing requirements. As previously disclosed, on October 16, 2020, Nasdaq notified the Company that its common stock had failed to maintain a minimum bid price of $1.00 over 30 consecutive business days as required by the Nasdaq Listing Rules. On December 17, 2020, Nasdaq provided confirmation to the Company that for the last 20 consecutive business days, from November 18 to December 14, 2020, the closing bid price of the Company's common stock had been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2).Reported Earnings • Nov 18Second quarter 2021 earnings released: US$0.039 loss per shareThe company reported a soft second quarter result with increased losses and weaker control over expenses, although revenues were improved. Second quarter 2021 results: Revenue: US$30.8m (up 8.8% from 2Q 2020). Net loss: US$1.49m (loss widened 22% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Oct 31New 90-day low: US$0.90The company is down 25% from its price of US$1.20 on 31 July 2020. The American market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is up 6.0% over the same period.Is New 90 Day High Low • Oct 15New 90-day low: US$0.91The company is down 32% from its price of US$1.35 on 17 July 2020. The American market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is up 10.0% over the same period.株主還元RDGTUS Consumer RetailingUS 市場7D6.5%-0.9%2.1%1Y-99.0%19.7%30.6%株主還元を見る業界別リターン: RDGT過去 1 年間で19.7 % の収益を上げたUS Consumer Retailing業界を下回りました。リターン対市場: RDGTは、過去 1 年間で30.6 % のリターンを上げたUS市場を下回りました。価格変動Is RDGT's price volatile compared to industry and market?RDGT volatilityRDGT Average Weekly Movement42.5%Consumer Retailing Industry Average Movement5.3%Market Average Movement7.2%10% most volatile stocks in US Market16.1%10% least volatile stocks in US Market3.2%安定した株価: RDGTの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: RDGTの 週次ボラティリティ は、過去 1 年間で27%から43%に増加しました。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/a61Frank Zhaowww.ridgetch.comリジテック社は、中華人民共和国で医薬品およびその他のヘルスケア製品の卸売業を営んでいる。3つのセグメントで事業を展開：小売ドラッグストア、オンライン薬局、医薬品卸売。同社は、医療用医薬品、一般用医薬品、栄養補助食品、漢方薬、パーソナルケア製品、ファミリーケア製品、医療機器などの医薬品や、消耗品、季節用品、販促品などのコンビニエンス製品のオフラインおよびオンラインでの卸売りを行っている。また、健康食品、化粧品、日用品などのヘルスケア商品も販売している。旧社名は株式会社チャイナジョー薬局で、2024年2月に株式会社リジテックに社名変更した。リジテック社の本社は中国杭州市にある。もっと見るRidgetech, Inc. 基礎のまとめRidgetech の収益と売上を時価総額と比較するとどうか。RDGT 基礎統計学時価総額US$197.48k収益（TTM）-US$2.01m売上高(TTM)US$119.94m0.0xP/Sレシオ-0.1xPER（株価収益率RDGT は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計RDGT 損益計算書（TTM）収益US$119.94m売上原価US$116.05m売上総利益US$3.89mその他の費用US$5.89m収益-US$2.01m直近の収益報告Sep 30, 2025次回決算日該当なし一株当たり利益（EPS）-16.46グロス・マージン3.24%純利益率-1.67%有利子負債／自己資本比率15.7%RDGT の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/07 14:43終値2026/05/07 00:00収益2025/09/30年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Ridgetech, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Mar 25New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$2.43m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (35% average weekly change). Shareholders have been substantially diluted in the past year (196% increase in shares outstanding). Market cap is less than US$10m (US$2.43m market cap).
Reported Earnings • Mar 08First half 2026 earnings released: US$0.01 loss per share (vs US$0.42 loss in 1H 2025)First half 2026 results: US$0.01 loss per share (improved from US$0.42 loss in 1H 2025). Revenue: US$62.8m (down 12% from 1H 2025). Net loss: US$60.2k (loss narrowed 97% from 1H 2025).
New Risk • Feb 13New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 6.9% per year over the past 5 years. Shareholders have been substantially diluted in the past year (196% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported March 2025 fiscal period end). Market cap is less than US$100m (US$30.9m market cap).
Buy Or Sell Opportunity • Jan 15Now 27% undervaluedOver the last 90 days, the stock has risen 47% to US$2.36. The fair value is estimated to be US$3.22, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.8% over the last 3 years. Earnings per share has grown by 61%.
お知らせ • Dec 30Ridgetech, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.Ridgetech, Inc. has filed a Follow-on Equity Offering in the amount of $200 million. Security Name: Ordinary Shares Security Type: Common Stock Transaction Features: At the Market Offering
Buy Or Sell Opportunity • Nov 20Now 27% undervaluedOver the last 90 days, the stock has risen 236% to US$4.17. The fair value is estimated to be US$5.72, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.8% over the last 3 years. Earnings per share has grown by 61%.
New Risk • Mar 25New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$2.43m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (35% average weekly change). Shareholders have been substantially diluted in the past year (196% increase in shares outstanding). Market cap is less than US$10m (US$2.43m market cap).
Reported Earnings • Mar 08First half 2026 earnings released: US$0.01 loss per share (vs US$0.42 loss in 1H 2025)First half 2026 results: US$0.01 loss per share (improved from US$0.42 loss in 1H 2025). Revenue: US$62.8m (down 12% from 1H 2025). Net loss: US$60.2k (loss narrowed 97% from 1H 2025).
New Risk • Feb 13New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 6.9% per year over the past 5 years. Shareholders have been substantially diluted in the past year (196% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported March 2025 fiscal period end). Market cap is less than US$100m (US$30.9m market cap).
Buy Or Sell Opportunity • Jan 15Now 27% undervaluedOver the last 90 days, the stock has risen 47% to US$2.36. The fair value is estimated to be US$3.22, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.8% over the last 3 years. Earnings per share has grown by 61%.
お知らせ • Dec 30Ridgetech, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.Ridgetech, Inc. has filed a Follow-on Equity Offering in the amount of $200 million. Security Name: Ordinary Shares Security Type: Common Stock Transaction Features: At the Market Offering
Buy Or Sell Opportunity • Nov 20Now 27% undervaluedOver the last 90 days, the stock has risen 236% to US$4.17. The fair value is estimated to be US$5.72, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.8% over the last 3 years. Earnings per share has grown by 61%.
お知らせ • Nov 13Ridgetech, Inc., Annual General Meeting, Dec 12, 2025Ridgetech, Inc., Annual General Meeting, Dec 12, 2025, at 09:00 China Standard Time. Location: 5th floor, building 6, no. 100, 18th street, baiyang sub-district, qiantang district, zhejiang province, p. r. china, 310008., hangzhou China
お知らせ • Oct 23Ridgetech, Inc. has withdrawn its Follow-on Equity Offering in the amount of $5 million.Ridgetech, Inc. has withdrawn its Follow-on Equity Offering in the amount of $5 million. Security Name: Ordinary Shares Security Type: Common Stock
お知らせ • Sep 26Ridgetech, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.Ridgetech, Inc. has filed a Follow-on Equity Offering in the amount of $5 million. Security Name: Ordinary Shares Security Type: Common Stock
Reported Earnings • Jul 29Full year 2025 earnings released: US$0.26 loss per share (vs US$2.93 loss in FY 2024)Full year 2025 results: US$0.26 loss per share (improved from US$2.93 loss in FY 2024). Revenue: US$120.0m (down 22% from FY 2024). Net loss: US$1.46m (loss narrowed 66% from FY 2024).
New Risk • Mar 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$15m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 23% per year over the past 5 years. Shareholders have been substantially diluted in the past year (267% increase in shares outstanding). Market cap is less than US$10m (US$5.80m market cap).
お知らせ • Feb 07China Jo-Jo Drugstores, Inc., Annual General Meeting, Feb 25, 2025China Jo-Jo Drugstores, Inc., Annual General Meeting, Feb 25, 2025, at 10:00 China Standard Time. Location: located at 4th floor, building 5, renxin yaju, gon, gong shu district, zhejiang, hangzhou city, China
New Risk • Jan 30New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.82m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$15m free cash flow). Earnings have declined by 23% per year over the past 5 years. Shareholders have been substantially diluted in the past year (267% increase in shares outstanding). Market cap is less than US$10m (US$9.82m market cap).
Reported Earnings • Jan 16First half 2025 earnings released: US$0.42 loss per share (vs US$0.77 loss in 1H 2024)First half 2025 results: US$0.42 loss per share. Revenue: US$71.2m (down 9.4% from 1H 2024). Net loss: US$2.28m (loss widened 146% from 1H 2024).
分析記事 • Oct 30China Jo-Jo Drugstores, Inc. (NASDAQ:CJJD) Stocks Shoot Up 32% But Its P/S Still Looks ReasonableChina Jo-Jo Drugstores, Inc. ( NASDAQ:CJJD ) shareholders are no doubt pleased to see that the share price has bounced...
New Risk • Oct 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 36% per year over the past 5 years. Shareholders have been substantially diluted in the past year (295% increase in shares outstanding). Minor Risk Market cap is less than US$100m (US$14.8m market cap).
New Risk • Aug 09New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.72m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 36% per year over the past 5 years. Shareholders have been substantially diluted in the past year (294% increase in shares outstanding). Market cap is less than US$10m (US$9.72m market cap). Minor Risk Share price has been volatile over the past 3 months (12% average weekly change).
Reported Earnings • Aug 01Full year 2024 earnings released: US$2.93 loss per share (vs US$41.46 loss in FY 2023)Full year 2024 results: US$2.93 loss per share (improved from US$41.46 loss in FY 2023). Revenue: US$154.5m (up 3.8% from FY 2023). Net loss: US$4.23m (loss narrowed 80% from FY 2023).
お知らせ • Jun 01China Jo-Jo Drugstores, Inc. Announces Resignation of Pingfan Wu as Member of the Board of DirectorsChina Jo-Jo Drugstores, Inc. announced that Ms. Pingfan Wu has resigned from her position as a member of the board of directors (the "Board") due to personal reasons, effective on May 31, 2024. The resignation of Ms. Wu did not result from any disagreement with the Company on any matter relating to the Company's business operations, financial reporting or controls, policies or practices.
お知らせ • Apr 30China Jo-Jo Drugstores, Inc. has filed a Follow-on Equity Offering in the amount of $1.53 million.China Jo-Jo Drugstores, Inc. has filed a Follow-on Equity Offering in the amount of $1.53 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 900,000 Price\Range: $1.7 Transaction Features: Registered Direct Offering
New Risk • Apr 01New major risk - Revenue and earnings growthRevenue has declined by 9.5% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 9.5% over the past year. Shareholders have been substantially diluted in the past year (65% increase in shares outstanding). Market cap is less than US$10m (US$5.30m market cap). Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Share price has been volatile over the past 3 months (13% average weekly change).
New Risk • Jan 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (294% increase in shares outstanding). Market cap is less than US$10m (US$7.47m market cap). Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Share price has been volatile over the past 3 months (12% average weekly change). Share price has been volatile over the past 3 months (12% average weekly change).
お知らせ • Nov 15China Jo-Jo Drugstores, Inc., Annual General Meeting, Nov 16, 2023China Jo-Jo Drugstores, Inc., Annual General Meeting, Nov 16, 2023, at 21:00 US Eastern Standard Time. Location: Hai Wai Hai Tongxin Mansion Floor 6, Gong Shu District, Hangzhou City, Zhejiang Province, P. R. China, 310008 Zhejiang China Agenda: To elect six directors to serve until the next Annual Meeting or until their successors are duly elected and qualified;to ratify the appointment of YCM CPA, Inc. as the Company's independent registered public accounting firm for the fiscal year ending March 31,2024; to approve by ordinary resolution the proposed reverse stock split and consolidation of the Company's issued and outstanding ordinary shares;to approve by ordinary resolution the increase of authorized share capital;to approve by special resolution the Amendment of the Memorandum and Articles of Association of the Company to effect the reverse stock split and consolidation of the Company's issued and outstanding ordinary shares, and the increase of authorized share capital;to approve the Third Amended and Restated 2010 Equity Incentive Plan; and to transact such other business as may properly come before the Annual Meeting or any adjournment thereof.
New Risk • Jun 27New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.89m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (36% average weekly change). Shareholders have been substantially diluted in the past year (over 5x increase in shares outstanding). Market cap is less than US$10m (US$9.89m market cap).
お知らせ • Jun 18China Jo-Jo Drugstores Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price DeficiencyOn June 16, 2023, China Jo-Jo Drugstores, Inc. announced that on June 15, 2023, the company has received a notification letter from Nasdaq Listing Qualifications Department (‘Nasdaq’) notifying the Company that it is not in compliance with the minimum bid price requirement from May 3, 2023 through June 14, 2023. As set forth in Nasdaq Listing Rules 5550(a)(2) (‘Nasdaq Listing Rule’), it requires that the closing bid price for the Company's ordinary shares listed on Nasdaq be maintained at a minimum of USD 1.00 and failure to meet it for 30 consecutive trading days constitutes a compliance deficiency. The notification has no immediate effect on the listing of the Company's ordinary shares on Nasdaq. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days from the date of notification, or until December 12, 2023, to regain compliance with the minimum bid price requirement, during which time the Company's ordinary shares will continue to trade on the Nasdaq Capital Market. If at any time during this 180 day period, or before December 12, 2023, the closing bid price of the Company's ordinary shares is at least USD 1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written notification that the Company has achieved compliance with the minimum bid price requirement. In the event the Company does not regain compliance by December 12, 2023, the Company may be eligible for additional time to regain compliance, if the Company provide written notice of its intention to cure the deficiency during the second compliance period and is in compliance with the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market. The company intends to monitor the closing bid price of its ordinary shares between now and December 12, 2023. In the event the Company is not eligible for additional time to regain compliance with the Nasdaq requirements towards the end of the first compliance period, the company's Board of Directors will consider options that may be available to achieve compliance.
Reported Earnings • Jun 16Full year 2023 earnings released: US$2.07 loss per share (vs US$0.92 loss in FY 2022)Full year 2023 results: US$2.07 loss per share (further deteriorated from US$0.92 loss in FY 2022). Revenue: US$148.8m (down 9.5% from FY 2022). Net loss: US$21.1m (loss widened US$17.9m from FY 2022).
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Independent Director Pingfan Wu was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Jul 29Full year 2022 earnings released: US$0.92 loss per share (vs US$2.39 loss in FY 2021)Full year 2022 results: US$0.92 loss per share (up from US$2.39 loss in FY 2021). Revenue: US$164.4m (up 24% from FY 2021). Net loss: US$3.19m (loss narrowed 61% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has fallen by 43% per year, which means it is performing significantly worse than earnings.
Seeking Alpha • Jul 28China Jo - Jo Drugstores GAAP EPS of -$0.92, revenue of $164.39MChina Jo - Jo Drugstores press release (NASDAQ:CJJD): FY GAAP EPS of -$0.92. Revenue of $164.39M (+23.5% Y/Y). Revenue increased by 23.5% to $164.39 million for the fiscal year ended March 31, 2022 from $133.13 million for the same period of last year. Gross profit increased by 24.9% to $36.52 million for the fiscal year ended March 31, 2022 from $29.24 million for the same period of last year. Gross margin increased by 0.2 percentage points to 22.2% for the fiscal year ended March 31, 2022 from 22.0% for the same period of last year. Revenue for the fiscal year ended March 31, 2022 increased by $31.25 million, or 23.5%, to $164.39 million from $133.13 million for the same period of last year. The increase in revenue was primarily due to the growth in retail drugstores, online pharmacy and wholesale business.
お知らせ • Apr 28China Jo-Jo Drugstores Regains Compliance with Nasdaq Minimum Bid Price RequirementChina Jo-Jo Drugstores, Inc. announced on April 27, 2022 that it received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on April 25, 2022, notifying the Company that it has regained compliance with the Nasdaq Capital Market's minimum bid price requirement and the matter is closed. On July 26, 2021, the Company was first notified by Nasdaq its failure to maintain a minimum bid price of $1.00 per share for 30 consecutive trading days under Nasdaq Listing Rules 5550(a)(2) and 5810(c)(3)(A), and was given its first 180-day extension, or until January 24, 2022 to regain compliance. On January 25, 2022, the Company received a second 180-day extension from Nasdaq or until July 25, 2022 to regain compliance. Effective April 7, 2022, the Company effected a 1-for-12 reverse stock split. The letter dated April 25, 2022 the Company received from Nasdaq noted that as of April 22, 2022, the Company evidenced a closing bid price of its ordinary shares at or greater than the $1.00 per share minimum requirement for the last 11 consecutive business days, from April 7, 2022 through April 22, 2022. Nasdaq stated that accordingly, Jo-Jo Drugstores has regained compliance with Nasdaq Marketplace Rule 5550(a)(2) and the matter is closed.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Independent Director Pingfan Wu was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jan 27China Jo-Jo Drugstores Granted Extension to Meet Nasdaq Minimum Bid Price RequirementChina Jo-Jo Drugstores, Inc. announced that on January 25, 2022, the Company received another 180 calendar day extension from Nasdaq's Listing Qualifications Department to meet Nasdaq's continuing listing requirements by maintaining a minimum bid price per share of $1.00 for a minimum of 10 consecutive trading days. The Company now has until July 25, 2022 to regain compliance. If at any time before July 25, 2022, the bid price of the Company's ordinary shares closes at or above $1.00 per share for a minimum of 10 consecutive trading days, the Company will regain compliance with the Nasdaq Listing Rules, and the matter will be closed. The Company was first notified by Nasdaq of its failure to maintain a minimum bid price of $1.00 per share for 30 consecutive trading days under Nasdaq Listing Rules 5550(a)(2) and 5810(c)(3)(A) on July 26, 2021, and was given until January 24, 2022 to regain compliance.
Reported Earnings • Jan 22First half 2022 earnings releasedFirst half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (up US$1.73m from 1H 2021). Profit margin: (up from net loss in 1H 2021). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.
Board Change • Nov 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Independent Director Pingfan Wu was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Jul 01Full year 2021 earnings released: US$0.20 loss per share (vs US$0.18 loss in FY 2020)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2021 results: Revenue: US$133.1m (up 14% from FY 2020). Net loss: US$8.12m (loss widened 40% from FY 2020). Like-for-like sales growth: Down 1.3% vs FY 2020 Over the last 3 years on average, earnings per share has increased by 62% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Mar 05New 90-day low: US$0.98The company is down 11% from its price of US$1.10 on 04 December 2020. The American market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is down 10.0% over the same period.
Reported Earnings • Feb 14Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.016 profit in 3Q 2020)The company reported a soft third quarter result with weaker earnings and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: US$35.5m (up 6.5% from 3Q 2020). Net loss: US$6.26m (down US$6.79m from profit in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
分析記事 • Feb 09China Jo-Jo Drugstores' (NASDAQ:CJJD) Stock Price Has Reduced 24% In The Past Five YearsIdeally, your overall portfolio should beat the market average. But the main game is to find enough winners to more...
Is New 90 Day High Low • Feb 06New 90-day high: US$1.24The company is up 16% from its price of US$1.07 on 06 November 2020. The American market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is up 2.0% over the same period.
Is New 90 Day High Low • Jan 12New 90-day high: US$1.15The company is up 22% from its price of US$0.94 on 13 October 2020. The American market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is up 2.0% over the same period.
お知らせ • Dec 24China Jo-Jo Drugstores Regains Compliance with Nasdaq Minimum Bid Price RequirementChina Jo-Jo Drugstores, Inc., on December 23, 2020 announced that it has received notification from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which concerns minimum bid price listing requirements. As previously disclosed, on October 16, 2020, Nasdaq notified the Company that its common stock had failed to maintain a minimum bid price of $1.00 over 30 consecutive business days as required by the Nasdaq Listing Rules. On December 17, 2020, Nasdaq provided confirmation to the Company that for the last 20 consecutive business days, from November 18 to December 14, 2020, the closing bid price of the Company's common stock had been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2).
Reported Earnings • Nov 18Second quarter 2021 earnings released: US$0.039 loss per shareThe company reported a soft second quarter result with increased losses and weaker control over expenses, although revenues were improved. Second quarter 2021 results: Revenue: US$30.8m (up 8.8% from 2Q 2020). Net loss: US$1.49m (loss widened 22% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Oct 31New 90-day low: US$0.90The company is down 25% from its price of US$1.20 on 31 July 2020. The American market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is up 6.0% over the same period.
Is New 90 Day High Low • Oct 15New 90-day low: US$0.91The company is down 32% from its price of US$1.35 on 17 July 2020. The American market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is up 10.0% over the same period.
